Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Carcinogenesis|July 31, 2012
Genetic variation and alterations of genes involved in NFκB/TNFAIP3- and NLRP3-inflammasome signaling affect susceptibility and outcome of colorectal cancerJonas Ungerbäck, Dimitri Belenki, Aksa Jawad ul-Hassan, et al.
Journal of Neuropathology and Experimental Neurology|March 10, 2026
Quantification of Ki-67 labeling index in pediatric brain tumor immunohistochemistry imagesChristoforos Spyretos, Juan Manuel Pardo Ladino, Hakon Andersen Blomstrand, et al.
Eclinicalmedicine|November 21, 2024
Total neoadjuvant treatment using short-course radiotherapy and four CAPOX cycles in locally advanced rectal cancer with high-risk criteria for recurrence: a Swedish nationwide cohort study (LARCT-US)Bengt Glimelius, Tanweera Khan, Karin Adolfsson, et al.
The Lancet. Oncology|October 30, 2025
Physical examinations and whole-body imaging versus physical examinations alone during follow-up after radical surgery of stage IIB-C and III cutaneous malignant melanoma (TRIM): an interim analysis of a multicentre, randomised, phase 3 trial in SwedenCecilia O Ladjevardi, Ylva Naeser, Ulf Dyrke, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 20, 2023
Isolated Hepatic Perfusion With Melphalan for Patients With Isolated Uveal Melanoma Liver Metastases: A Multicenter, Randomized, Open-Label, Phase III Trial (the SCANDIUM Trial)Roger Olofsson Bagge, Axel Nelson, Amir Shafazand, et al.
Genome Medicine|January 2, 2020
Digital twins to personalize medicineBergthor Björnsson, Carl Borrebaeck, Nils Elander, et al.
Annals of Surgery|February 29, 2024
Survival and Quality of Life After Isolated Hepatic Perfusion With Melphalan as a Treatment for Uveal Melanoma Liver Metastases: Final Results From the Phase III Randomized Controlled Trial SCANDIUMRoger Olofsson Bagge, Axel Nelson, Amir Shafazand, et al.
The Lancet. Gastroenterology & Hepatology|January 18, 2024
Neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer (NORPACT-1): a multicentre, randomised, phase 2 trialKnut Jørgen Labori, Svein Olav Bratlie, Bodil Andersson, et al.
Pageof 2